Mohamed Albekery - Academia.edu (original) (raw)
Uploads
Papers by Mohamed Albekery
American journal of nephrology, Apr 26, 2024
SAGE Open Medicine
Objective: The aim of this study is to compare the adherence to the guidelines in patients presen... more Objective: The aim of this study is to compare the adherence to the guidelines in patients presenting with hyponatremia defined as a sodium (Na) level ⩽120 mEq/L, treated with 3% hypertonic saline or normal saline. The comparison included 3% hypertonic saline use, safe serum sodium increases within 24 and 48 h, frequency of hyponatremia-related complications, and length of stay. Methods: This retrospective observational study enrolled 122 patients with serum sodium ⩽120 mEq/L admitted to the Internal Medicine Department, King Abdulaziz Medical City, National Guard-Health Affairs (NGHA), Riyadh, Saudi Arabia, from January 2016 to December 2017. The patients were treated with either 3% hypertonic saline or normal saline. Results: Of the 122 patients, 105 (83.3%) received normal saline, and 17 (13.5%) received hypertonic saline. In the normal saline group, the mean serum sodium increase at 24 h was lower (6.60 ± 4.75) compared to the hypertonic saline group (9.24 ± 5.04). The length of...
Objectives: The aim of this study is to evaluate the efficacy and safety of Ruxolitinib among Mye... more Objectives: The aim of this study is to evaluate the efficacy and safety of Ruxolitinib among Myelofibrosis patients in real life compared to published data. Methods: In this retrospective observational chart review study we reviewed the medical records for all patients diagnosed with Myelofibrosis in King Abdulaziz Medical City who has received Ruxolitinib from March 1, 2012-December 1, 2015. The efficacy and safety results of Ruxolitinib were compared with published data. Results: A total of 20 patients were included. The average age was 63.3 (SD=11.6) years, with 55% of females. Efficacy: At week 24, only 20% of the study participant achieved spleen size reduction equal to or more than 20% with total average of 8% reduction in the spleen size as compared to 31.60% in COMFORT-1 study (p ≤ 0.001), The highest symptoms reduction observed with fatigue and bone pain (45% and 40% of the affected patients respectively) followed by Abdominal distress (35%) whereas no statistically signif...
American journal of nephrology, Apr 26, 2024
SAGE Open Medicine
Objective: The aim of this study is to compare the adherence to the guidelines in patients presen... more Objective: The aim of this study is to compare the adherence to the guidelines in patients presenting with hyponatremia defined as a sodium (Na) level ⩽120 mEq/L, treated with 3% hypertonic saline or normal saline. The comparison included 3% hypertonic saline use, safe serum sodium increases within 24 and 48 h, frequency of hyponatremia-related complications, and length of stay. Methods: This retrospective observational study enrolled 122 patients with serum sodium ⩽120 mEq/L admitted to the Internal Medicine Department, King Abdulaziz Medical City, National Guard-Health Affairs (NGHA), Riyadh, Saudi Arabia, from January 2016 to December 2017. The patients were treated with either 3% hypertonic saline or normal saline. Results: Of the 122 patients, 105 (83.3%) received normal saline, and 17 (13.5%) received hypertonic saline. In the normal saline group, the mean serum sodium increase at 24 h was lower (6.60 ± 4.75) compared to the hypertonic saline group (9.24 ± 5.04). The length of...
Objectives: The aim of this study is to evaluate the efficacy and safety of Ruxolitinib among Mye... more Objectives: The aim of this study is to evaluate the efficacy and safety of Ruxolitinib among Myelofibrosis patients in real life compared to published data. Methods: In this retrospective observational chart review study we reviewed the medical records for all patients diagnosed with Myelofibrosis in King Abdulaziz Medical City who has received Ruxolitinib from March 1, 2012-December 1, 2015. The efficacy and safety results of Ruxolitinib were compared with published data. Results: A total of 20 patients were included. The average age was 63.3 (SD=11.6) years, with 55% of females. Efficacy: At week 24, only 20% of the study participant achieved spleen size reduction equal to or more than 20% with total average of 8% reduction in the spleen size as compared to 31.60% in COMFORT-1 study (p ≤ 0.001), The highest symptoms reduction observed with fatigue and bone pain (45% and 40% of the affected patients respectively) followed by Abdominal distress (35%) whereas no statistically signif...